Creatine for Depressed Male and Female Methamphetamine Users
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-59
SponsorMontana State University
About this trial
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
Eligibility criteria
Qualifiers
Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse
Current diagnosis of major depressive disorder (primary or substance-induced)
Current diagnosis of an anxiety disorder (primary or substance-induced)
Current Hamilton Depression Rating scale score > or = to 16
Disqualifiers
Persons unable to provide adequate informed consent
Persons who are at clinically significant suicidal or homicidal risk
Primary substance-related diagnosis other than methamphetamine dependence or abuse
Positive pregnancy test (females only)
Trial design
Treatments tested in this trial
- Creatine monohydrate
Treatment groups
29 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov